- Home
- AMPL vs ETNB Comparison
AMPL vs ETNB Comparison
Compare AMPL & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- ETNB
- Stock Information
- Founded
- AMPL 2012
- ETNB 2018
- Country
- AMPL United States
- ETNB United States
- Employees
- AMPL N/A
- ETNB N/A
- Industry
- AMPL EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- ETNB Health Care
- Exchange
- AMPL Nasdaq
- ETNB Nasdaq
- Market Cap
- AMPL 1.7B
- ETNB 1.5B
- IPO Year
- AMPL 2021
- ETNB 2019
- Fundamental
- Price
- AMPL $11.43
- ETNB $9.03
- Analyst Decision
- AMPL Buy
- ETNB Strong Buy
- Analyst Count
- AMPL 10
- ETNB 9
- Target Price
- AMPL $13.70
- ETNB $26.63
- AVG Volume (30 Days)
- AMPL 2.0M
- ETNB 1.6M
- Earning Date
- AMPL 08-06-2025
- ETNB 08-07-2025
- Dividend Yield
- AMPL N/A
- ETNB N/A
- EPS Growth
- AMPL N/A
- ETNB N/A
- EPS
- AMPL N/A
- ETNB N/A
- Revenue
- AMPL $316,571,000.00
- ETNB N/A
- Revenue This Year
- AMPL $15.04
- ETNB N/A
- Revenue Next Year
- AMPL $12.65
- ETNB N/A
- P/E Ratio
- AMPL N/A
- ETNB N/A
- Revenue Growth
- AMPL 9.93
- ETNB N/A
- 52 Week Low
- AMPL $7.55
- ETNB $4.16
- 52 Week High
- AMPL $14.88
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- AMPL 47.02
- ETNB 50.63
- Support Level
- AMPL $10.96
- ETNB $9.07
- Resistance Level
- AMPL $11.95
- ETNB $9.62
- Average True Range (ATR)
- AMPL 0.44
- ETNB 0.38
- MACD
- AMPL 0.04
- ETNB 0.06
- Stochastic Oscillator
- AMPL 61.76
- ETNB 72.45
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).